VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial

Dynavax Technologies Executive Compensation (FY24)

DVAX · Executive and director compensation, fiscal 2022 to 2024
Chief executive, fiscal 2024
◇
Ryan Spencer
Latest say-on-pay support
=
June 11, 2025
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Dynavax Technologies

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): June 17, 2025
11 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Dynavax Technologies brief$500Get the executive brief
Velarion Intel, one year, every company
297 figures on this page: 288 cited to the filing that reported them, 9 calculated from figures it prints. See the citations

More on Dynavax Technologies

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Ryan Spencer: $5,810,736 → $8,210,775 (41.3% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Dynavax Technologies' chief executive and what were they paid?
Total compensation for Ryan Spencer, Chief Executive Officer and Director, came to $8,210,775 in fiscal 2024. Compared with the $5,810,736 reported for fiscal 2023, Spencer's total was 41.3% higher.
What was Dynavax Technologies' say-on-pay result?
Shareholders supported the say-on-pay proposal with 92.4% of votes cast for or against in favor at the meeting held June 11, 2025 for fiscal 2024.
Which companies are in Dynavax Technologies' peer group?
The disclosed peer group names Acadia Pharmaceuticals, Inc., Agenus, Inc., Alector, Inc., Amicus Therapeutics, Inc. and Collegium Pharmaceuticals, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ryan Spencer
Chief Executive Officer and Director
◇—◇◇◇—◇◇
David Novack
President and Chief Operating Officer
◇—◇◇◇—◇◇
Kelly MacDonald
Senior Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Robert Janssen
Chief Medical Officer and Senior Vice President
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ryan Spencer
Chief Executive Officer and Director
◇—◇◇◇—◇◇
David Novack
President and Chief Operating Officer
◇—◇◇◇—◇◇
Kelly MacDonald
Senior Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Robert Janssen
Chief Medical Officer and Senior Vice President
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ryan Spencer
Chief Executive Officer and Director
◇—◇◇◇—◇◇
David Novack
President and Chief Operating Officer
◇—◇◇◇—◇◇
John Slebir
Senior Vice President and General Counsel
◇—◇◇◇—◇◇
Kelly MacDonald
Senior Vice President and Chief Financial Officer
◇◇◇◇◇—◇◇
Robert Janssen
Chief Medical Officer and Senior Vice President
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
David F. Novack—◇——◇——◇
David F. NovackOPTION◇——◇—◇◇
David F. NovackPSU◇◇◇—◇—◇
John L. SlebirOPTION◇——◇—◇◇
John L. SlebirPSU◇◇◇—◇—◇
John L. Slebir—◇——◇——◇
Kelly MacDonaldPSU◇◇◇—◇—◇
Kelly MacDonald—◇——◇——◇
Kelly MacDonaldOPTION◇——◇—◇◇
Robert JanssenOPTION◇——◇—◇◇
Robert Janssen—◇——◇——◇
Robert JanssenPSU◇◇◇—◇—◇
Ryan SpencerPSU◇◇◇—◇—◇
Ryan SpencerOPTION◇——◇—◇◇
Ryan Spencer—◇——◇——◇
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Ryan SpencerOption◇—◇2/14/2031
PSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇2/15/2030
PSU◇◇——
RSU◇◇——
Option◇—◇2/9/2029
David NovackOption◇—◇2/15/2030
PSU◇◇——
RSU◇◇——
Option◇—◇2/9/2029
PSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇2/2/2028
John SlebirOption◇—◇2/14/2031
PSU◇◇——
RSU◇◇——
Option◇—◇2/15/2030
PSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇2/9/2029
Kelly MacDonaldOption◇—◇2/15/2031
PSU◇◇——
RSU◇◇——
Option◇—◇2/15/2030
PSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇2/9/2029
Robert JanssenOption◇—◇2/15/2031
PSU◇◇——
RSU◇◇——
Option◇—◇2/15/2030
PSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇2/9/2029
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Scott Myers
Board chair
◇◇◇———◇
Peggy V. Phillips
◇◇◇———◇
Peter R. Paradiso
◇◇◇———◇
Julie Eastland
◇◇◇———◇
Daniel L. Kisner
◇◇◇———◇
Elaine Sun
◇◇◇———◇
Francis R. Cano
◇◇◇———◇
Brent MacGregor
◇◇◇———◇
Lauren Silvernail, Ryan Spencer and Emilio Emini served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • Acadia Pharmaceuticals, Inc. ACAD
  • Agenus, Inc. AGEN
  • Alector, Inc. ALEC
  • Amicus Therapeutics, Inc. FOLD
  • Collegium Pharmaceuticals, Inc. COLL
  • Corcept Therapeutics, Inc. CORT
  • Eagle Pharmaceuticals, Inc. EGRX
  • Exelixis, Inc. EXEL
  • Fibrogen, Inc. symbol not shown
  • Harmony Biosciences, Inc. HRMY
  • Ionis Pharmaceuticals, Inc. IONS
  • Ironwood Pharmaceuticals, Inc. IRWD
  • Mannkind Corp. MNKD
  • Novavax, Inc. NVAX
  • Pacira BioSciences, Inc. PCRX
  • PTC Therapeutics, Inc. PTCT
  • Supernus Pharmaceuticals, Inc. SUPN
  • Travere Therapeutics, Inc. TVTX
  • Vaxcyte, Inc. PCVX
  • Vir Biotechnology, Inc. VIR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024June 11, 2025=◇◇◇
2023April 11, 2024=◇◇◇
2022May 26, 2023=◇◇◇
2021April 4, 2022=◇◇◇
2020April 6, 2021=◇◇◇
2019May 28, 2020=◇◇◇
2018May 30, 2019=◇◇◇
2017May 31, 2018=◇◇◇
2015May 31, 2016=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Ryan Spencer (Chief Executive Officer and Director), FY2024 total compensation $8,210,775 (base salary $835,001) [exec_comp, SEC accession 0000930413-25-001273, filed 2025-04-17]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when Dynavax Technologies files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Dynavax Technologies disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Dynavax Technologies sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Dynavax Technologies' disclosed peer group is defensible, who names Dynavax Technologies back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
297 figures on this page: 288 cited to the filing that reported them, 9 calculated from figures it prints.
288 cited to the filing
9 calculated from the filing

Documents cited

  1. 0001193125-25-141755
  2. 0000930413-25-001273
    DIRECTOR COMPENSATION TABLE & · Director Compensation table · OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END · Outstanding Equity Awards at Fiscal Year End · and 1 more section
  3. 0000950170-24-064556
  4. 0001140361-24-019367
  5. 0000950170-23-024566
  6. 0000950170-22-010765
  7. 0001564590-21-031417
  8. 0001564590-20-027622
  9. 0001564590-19-021246
  10. 0001564590-18-014932
  11. 0001564590-16-020169
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Dynavax Technologies executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/DVAX (accessed 2026).
Short form: data: Velarion

The paid brief for Dynavax Technologies

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
11 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Dynavax Technologies and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Dynavax Technologies discloses

The companies named in DVAX's own disclosed peer group.

Acadia Pharmaceuticals, Inc.Agenus, Inc.Alector, Inc.Amicus Therapeutics, Inc.Collegium Pharmaceuticals, Inc.Corcept Therapeutics, Inc.Eagle Pharmaceuticals, Inc.Exelixis, Inc.Harmony Biosciences, Inc.Ionis Pharmaceuticals, Inc.Ironwood Pharmaceuticals, Inc.Mannkind Corp.Novavax, Inc.Pacira BioSciences, Inc.PTC Therapeutics, Inc.Supernus Pharmaceuticals, Inc.Travere Therapeutics, Inc.Vaxcyte, Inc.Vir Biotechnology, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy